Sanofi

Sanofi (SNYNF) announced an update on their ongoing clinical study. Sanofi’s long term extension study NCT06033833 tracks how its asthma drug amlitelimab perfo...

has had a mixed run, with the share price climbing over the longer haul yet slipping in recent weeks, which raises a simple question for anyone looking at the s...

Regeneron Pharmaceuticals (REGN), Sanofi (SNYNF) announced an update on their ongoing clinical study. Sanofi and Regeneron have completed a new real-world stud...

TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $960 price target on Regeneron (REGN), saying the expanded agreement with Sanofi (SNY) enhances bot...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) are expanding their extensive, two-decade-long antibody partnership to jointly develop a...

Yves Herman / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced an expansion of their long-standing antibody collaboration, adding multiple next-generation, long-ac...

A prior litigation related to the collaboration was settled as part of the agreement, the companies said. Sylvain Thomas / Agence France-Presse / Getty Images...

Sanofi ( (FR:SAN) ) has issued an update. Sanofi and Regeneron have expanded their two-decade immunology alliance by adding four next-generation, long-acting a...

Sanofi SA (SNY) announced an update on their ongoing clinical study. Sanofi’s latest clinical update centers on a Phase 4 study called “Single Arm, Open-label...